TFPT

Summary

TFPT (TCF3 fusion partner, HGNC:13630) is a protein-coding gene on chromosome 19q13.42, encoding TCF3 fusion partner (P0C1Z6). Appears to promote apoptosis in a p53/TP53-independent manner.

Predicted to enable DNA binding activity. Involved in several processes, including apoptotic signaling pathway; chromatin remodeling; and regulation of nucleobase-containing compound metabolic process. Located in nucleoplasm. Part of Ino80 complex.

Source: NCBI Gene 29844 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 62 total
• MANE Select transcript: NM_013342

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13630
Approved symbol	TFPT
Name	TCF3 fusion partner
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	FB1, amida, INO80F
Ensembl gene	ENSG00000105619
Ensembl biotype	protein_coding
OMIM	609519
Entrez	29844

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 nonsense_mediated_decay

ENST00000391757, ENST00000391758, ENST00000391759, ENST00000420715, ENST00000911296, ENST00000911297

RefSeq mRNA: 2 — MANE Select: NM_013342 NM_001321792, NM_013342

CCDS: CCDS12878, CCDS82396

Canonical transcript exons

ENST00000391759 — 6 exons

Exon	Start	End
ENSE00000856131	54110051	54110121
ENSE00001509669	54115247	54115657
ENSE00003558994	54108026	54108244
ENSE00003595137	54114442	54114700
ENSE00003614840	54107020	54107169
ENSE00003623636	54108326	54108395

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 96.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.3944 / max 129.3115, expressed in 1796 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182590	6.0280	1736
182589	4.0708	1639
182588	2.2957	1143

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amygdala	UBERON:0001876	96.24	gold quality
temporal lobe	UBERON:0001871	96.21	gold quality
prefrontal cortex	UBERON:0000451	95.82	gold quality
anterior cingulate cortex	UBERON:0009835	95.72	gold quality
Ammon’s horn	UBERON:0001954	95.23	gold quality
frontal cortex	UBERON:0001870	95.11	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.01	gold quality
cerebral cortex	UBERON:0000956	94.85	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.74	gold quality
right frontal lobe	UBERON:0002810	94.39	gold quality
substantia nigra	UBERON:0002038	93.96	gold quality
putamen	UBERON:0001874	93.40	gold quality
hypothalamus	UBERON:0001898	93.36	gold quality
superior frontal gyrus	UBERON:0002661	92.85	gold quality
nucleus accumbens	UBERON:0001882	92.48	gold quality
caudate nucleus	UBERON:0001873	92.29	gold quality
brain	UBERON:0000955	92.17	gold quality
primary visual cortex	UBERON:0002436	91.32	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.49	gold quality
granulocyte	CL:0000094	89.26	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.86	gold quality
apex of heart	UBERON:0002098	88.77	gold quality
cerebellum	UBERON:0002037	88.72	gold quality
cerebellar hemisphere	UBERON:0002245	88.71	gold quality
cerebellar cortex	UBERON:0002129	88.67	gold quality
mucosa of transverse colon	UBERON:0004991	88.48	gold quality
prostate gland	UBERON:0002367	88.17	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	87.38	gold quality
spleen	UBERON:0002106	86.88	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.32
E-GEOD-75367	no	50.34

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
EAF1	Unknown
EAF2	Repression

Upstream regulators (CollecTRI, top): TCF3

Literature-anchored findings (GeneRIF, showing 4)

• Although p53 is a main regulator of apoptosis in mammalian cells, the Tfpt induced apoptosis appears p53-independent. (PMID:17041757)
• FB1 is an important binding partner and a functional regulator of U19/EAF2, EAF1, and/or ELL. (PMID:17395368)
• Characterization of the core promoters controlling the expression of PRPF31 and TFPT, a bi-directional gene-pair. (PMID:22723017)
• TCF3/E2A is Conserved Specific Coregulators of the p21:PUMA Expression Ratio. (PMID:23684607)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tfpt	ENSMUSG00000006335
rattus_norvegicus	Tfpt	ENSRNOG00000056098

Protein

Protein identifiers

TCF3 fusion partner — P0C1Z6 (reviewed: P0C1Z6)

Alternative names: INO80 complex subunit F, Protein FB1

All UniProt accessions (3): P0C1Z6, A8MTQ3, F8WDC1

UniProt curated annotations — full annotation on UniProt →

Function. Appears to promote apoptosis in a p53/TP53-independent manner. Putative regulatory component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair.

Subunit / interactions. Interacts with NOL3; translocates NOL3 into the nucleus and negatively regulated TFPT-induced cell death. Component of the chromatin remodeling INO80 complex; specifically part of a complex module associated with the N-terminus of INO80.

Subcellular location. Nucleus.

Disease relevance. A chromosomal aberration involving TFPT is a cause of pre-B-cell acute lymphoblastic leukemia (B-ALL). Inversion inv(19)(p13;q13) with TCF3.

Isoforms (2)

UniProt ID	Names	Canonical?
P0C1Z6-1	1	yes
P0C1Z6-2	2

RefSeq proteins (2): NP_001308721, NP_037474* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR033555	TFPT	Family
IPR056513	INO80F	Domain

Pfam: PF24245

UniProt features (14 total): modified residue 7, region of interest 3, chain 1, cross-link 1, splice variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0C1Z6-F1	67.81	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 249, 252, 216, 167, 172, 180, 188, 207

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-5689603	UCH proteinases
R-HSA-5696394	DNA Damage Recognition in GG-NER
R-HSA-392499	Metabolism of proteins
R-HSA-5688426	Deubiquitination
R-HSA-5696398	Nucleotide Excision Repair
R-HSA-5696399	Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-597592	Post-translational protein modification
R-HSA-73894	DNA Repair

MSigDB gene sets: 160 (showing top): GOBP_CHROMOSOME_ORGANIZATION, RRAGTTGT_UNKNOWN, GOZGIT_ESR1_TARGETS_DN, GOBP_TELOMERE_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_DNA_REPAIR, GOBP_REGULATION_OF_TELOMERE_MAINTENANCE, GOBP_APOPTOTIC_SIGNALING_PATHWAY, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_DNA_STRAND_ELONGATION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_DNA_REPAIR, LIAO_METASTASIS

GO Biological Process (17): telomere maintenance (GO:0000723), regulation of DNA replication (GO:0006275), DNA repair (GO:0006281), regulation of DNA repair (GO:0006282), DNA recombination (GO:0006310), chromatin remodeling (GO:0006338), regulation of chromosome organization (GO:0033044), positive regulation of apoptotic process (GO:0043065), positive regulation of DNA repair (GO:0045739), positive regulation of DNA-templated transcription (GO:0045893), regulation of embryonic development (GO:0045995), regulation of cell cycle (GO:0051726), regulation of DNA strand elongation (GO:0060382), apoptotic signaling pathway (GO:0097190), positive regulation of telomere maintenance in response to DNA damage (GO:1904507), apoptotic process (GO:0006915), DNA damage response (GO:0006974)

GO Molecular Function (2): DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), Ino80 complex (GO:0031011)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Deubiquitination	1
Global Genome Nucleotide Excision Repair (GG-NER)	1
Post-translational protein modification	1
DNA Repair	1
Nucleotide Excision Repair	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	3
regulation of DNA metabolic process	3
DNA repair	2
apoptotic process	2
positive regulation of response to stimulus	2
cellular anatomical structure	2
telomere organization	1
DNA replication	1
DNA damage response	1
regulation of cellular response to stress	1
chromatin organization	1
regulation of organelle organization	1
chromosome organization	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
regulation of DNA repair	1
positive regulation of DNA metabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
embryo development	1
regulation of multicellular organismal development	1
cell cycle	1
regulation of cellular process	1
DNA strand elongation	1
signal transduction	1
positive regulation of telomere maintenance	1
telomere maintenance in response to DNA damage	1
regulation of telomere maintenance in response to DNA damage	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to stress	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
nuclear chromosome	1
INO80-type complex	1

Protein interactions and networks

STRING

1252 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TFPT	PRPF31	Q8WWY3	839
TFPT	TCF3	P15883	823
TFPT	INO80E	Q8NBZ0	783
TFPT	HLF	Q16534	698
TFPT	NFRKB	Q6P4R8	617
TFPT	NDUFA3	O95167	603
TFPT	SRPX2	O60687	590
TFPT	PBX1	P40424	574
TFPT	TLE2	Q04725	559
TFPT	TLE6	Q9H808	549
TFPT	A0A087WTN9	A0A087WTN9	549
TFPT	IKZF1	Q13422	546
TFPT	CCNDBP1	O95273	532
TFPT	BTBD19	C9JJ37	527
TFPT	LENG1	Q96BZ8	504

IntAct

153 interactions, top by confidence:

A	B	Type	Score
RUVBL1	ZNHIT1	psi-mi:“MI:0914”(association)	0.860
TFPT	TPM3	psi-mi:“MI:0915”(physical association)	0.850
TPM3	TFPT	psi-mi:“MI:0915”(physical association)	0.850
UCHL5	PSMD11	psi-mi:“MI:0914”(association)	0.840
YY1	ACTL6A	psi-mi:“MI:0914”(association)	0.830
CCNDBP1	RPLP0	psi-mi:“MI:0914”(association)	0.800
INO80E	TFPT	psi-mi:“MI:0914”(association)	0.790
TFPT	UCHL5	psi-mi:“MI:0915”(physical association)	0.770
TFPT	CCNDBP1	psi-mi:“MI:0915”(physical association)	0.740
CCNDBP1	TFPT	psi-mi:“MI:0915”(physical association)	0.740
YY1	TFPT	psi-mi:“MI:0914”(association)	0.740
RUVBL2	POLR3A	psi-mi:“MI:0914”(association)	0.640
RUVBL1	POLR3A	psi-mi:“MI:0914”(association)	0.640
LRRC46	TFPT	psi-mi:“MI:0914”(association)	0.640
INO80E	ACTL6A	psi-mi:“MI:0914”(association)	0.640

BioGRID (234): TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), TFPT (Two-hybrid), CDCA7L (Two-hybrid), RPGRIP1 (Two-hybrid), HAUS1 (Two-hybrid), DYDC1 (Two-hybrid)

ESM2 similar proteins: A0A1B0GUS0, A0A5F9ZHS7, A7E346, A7MB34, A8MZG2, B2RU40, D4A9R4, O08574, O75593, P0C1Z6, P0CG20, Q0VG99, Q0ZCJ7, Q17QH7, Q29RM2, Q2KIS6, Q2M2S6, Q2M3G4, Q2NL68, Q32LE6, Q3U1J1, Q5JXC2, Q5R815, Q5SW24, Q61660, Q63247, Q6NZ36, Q6PBC9, Q6ZN01, Q6ZRI6, Q7TN08, Q7Z591, Q80VF6, Q86WR7, Q8BG26, Q8BP99, Q8BXQ8, Q8IYS4, Q8N9Y4, Q8NAV2

Diamond homologs: P0C1Z6, Q17QH7, Q3U1J1, Q9JMG6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
TFPT	“form complex”	“INO80 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 95 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Global Genome Nucleotide Excision Repair (GG-NER)	7	51.6×	6e-09
DNA Damage Recognition in GG-NER	8	36.8×	6e-09
Nucleotide Excision Repair	7	32.2×	2e-07
UCH proteinases	11	22.0×	7e-10
Deubiquitination	7	14.0×	5e-05
DNA Repair	7	11.1×	2e-04
HATs acetylate histones	8	10.2×	6e-05
Chromatin organization	6	7.9×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of telomere maintenance in response to DNA damage	10	135.4×	7e-18
regulation of DNA strand elongation	10	126.9×	1e-17
regulation of chromosome organization	10	112.8×	4e-17
regulation of embryonic development	12	47.8×	2e-15
positive regulation of DNA repair	11	47.5×	3e-14
regulation of DNA replication	10	44.1×	1e-12
regulation of DNA repair	11	36.6×	6e-13
DNA recombination	9	36.5×	1e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1268 predictions. Top by Δscore:

Variant	Effect	Δscore
19:54107169:TC:T	acceptor_loss	1.0000
19:54107170:C:CA	acceptor_loss	1.0000
19:54107170:C:CC	acceptor_gain	1.0000
19:54108321:CTCA:C	donor_loss	1.0000
19:54108322:TCAC:T	donor_loss	1.0000
19:54108323:CA:C	donor_loss	1.0000
19:54108324:ACCT:A	donor_gain	1.0000
19:54108325:CCTC:C	donor_gain	1.0000
19:54110047:TTAC:T	donor_loss	1.0000
19:54110048:TACC:T	donor_loss	1.0000
19:54110049:A:AG	donor_loss	1.0000
19:54110050:CC:C	donor_loss	1.0000
19:54110052:T:TA	donor_gain	1.0000
19:54110057:T:A	donor_gain	1.0000
19:54110120:ACCT:A	acceptor_loss	1.0000
19:54110121:CCTA:C	acceptor_loss	1.0000
19:54110123:T:G	acceptor_loss	1.0000
19:54114437:CCTA:C	donor_gain	1.0000
19:54114438:CTA:C	donor_loss	1.0000
19:54114439:TACCT:T	donor_loss	1.0000
19:54114440:A:AG	donor_loss	1.0000
19:54114441:CCTG:C	donor_gain	1.0000
19:54107165:TTAAT:T	acceptor_gain	0.9900
19:54107166:TAAT:T	acceptor_gain	0.9900
19:54107168:AT:A	acceptor_gain	0.9900
19:54107174:A:T	acceptor_gain	0.9900
19:54108027:TGC:T	donor_gain	0.9900
19:54108318:ACACT:A	donor_loss	0.9900
19:54108319:CACTC:C	donor_loss	0.9900
19:54108320:ACTCA:A	donor_loss	0.9900

AlphaMissense

1602 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:54110099:C:A	R102M	1.000
19:54114617:A:G	I36T	1.000
19:54114617:A:T	I36N	1.000
19:54114628:A:C	F32L	1.000
19:54114628:A:T	F32L	1.000
19:54114630:A:G	F32L	1.000
19:54110098:C:A	R102S	0.999
19:54110098:C:G	R102S	0.999
19:54114614:A:G	L37P	0.999
19:54114617:A:C	I36S	0.999
19:54114629:A:C	F32C	0.999
19:54114629:A:G	F32S	0.999
19:54114630:A:T	F32I	0.999
19:54114632:A:T	L31Q	0.999
19:54114641:A:G	L28S	0.999
19:54114670:G:C	F18L	0.999
19:54114670:G:T	F18L	0.999
19:54114672:A:G	F18L	0.999
19:54110066:A:G	L113P	0.998
19:54110096:A:G	L103P	0.998
19:54110099:C:G	R102T	0.998
19:54110116:G:C	N96K	0.998
19:54110116:G:T	N96K	0.998
19:54114481:C:A	K81N	0.998
19:54114481:C:G	K81N	0.998
19:54114614:A:T	L37Q	0.998
19:54114630:A:C	F32V	0.998
19:54114641:A:C	L28W	0.998
19:54108378:A:G	L124P	0.997
19:54108378:A:T	L124Q	0.997

dbSNP variants (sampled 300 via entrez): RS1000143142 (19:54117637 A>T), RS1001396359 (19:54107967 C>T), RS1001444775 (19:54112675 G>C), RS1001495557 (19:54112448 G>A), RS1001832480 (19:54111186 G>A), RS1002504705 (19:54113638 C>T), RS1003596568 (19:54109009 C>G,T), RS1003835673 (19:54109070 T>G), RS1003853352 (19:54114362 G>A,T), RS1004137244 (19:54108776 T>C), RS1004393522 (19:54114122 G>A), RS1005123064 (19:54109180 G>A), RS1005601392 (19:54106912 C>T), RS1006129096 (19:54110454 C>T), RS1006153147 (19:54106703 C>A,T)

Disease associations

OMIM: gene MIM:609519 | disease phenotypes: MIM:600138, MIM:268000

GenCC curated gene-disease

Mondo (2): retinitis pigmentosa 11 (MONDO:0010828), retinitis pigmentosa (MONDO:0019200)

Orphanet (1): Retinitis pigmentosa (Orphanet:791)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001762_104	Obesity-related traits	8.000000e-06
GCST001762_198	Obesity-related traits	3.000000e-06
GCST001762_787	Obesity-related traits	8.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004338	body weight
EFO:0005106	body composition measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684
C563991	Retinitis Pigmentosa 11 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Smoke	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
sodium arsenite	increases expression	1
coumarin	increases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Air Pollutants	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	increases expression	1
Quercetin	affects phosphorylation	1
Tretinoin	increases expression	1
Urethane	increases expression	1
Valproic Acid	increases methylation	1
Palmitic Acid	decreases phosphorylation	1
Okadaic Acid	increases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

237 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT05902962	PHASE1	COMPLETED	SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NCT06455826	PHASE1	COMPLETED	MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa